Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Changes in Stockholders' Deficit

v3.3.1.900
Consolidated Statement of Changes in Stockholders' Deficit - USD ($)
Common Stock [Member]
Preferred Series A [Member]
Preferred Series B [Member]
Additional Paid-In Capital [Member]
Deferred Compensation [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2013 [1] $ 33,229 $ 40,118 $ 20,237 $ 19,867,961 $ (32,897,657) $ (12,936,112)
Balance, shares at Dec. 31, 2013 [1] 33,229,093 40,118,013 20,237,459        
Issuance of common stock $ 6,277 3,916,823 $ 3,923,100
Issuance of common stock, shares 6,276,960            
Effect of reverse merger $ 5,548 $ (40,118) $ (20,237) 54,807
Effect of reverse merger, shares 5,548,404 (40,118,013) (20,237,459)        
Stock option exercise $ 5 693 $ 698
Stock option exercise, shares 4,506           (4,506)
Conversion of 2013 notes payable $ 14,447 9,014,813 $ 9,029,260
Conversion of 2013 notes payable, shares 14,446,777            
Conversion of 2014 notes payable $ 3,353 2,092,554 2,095,907
Conversion of 2014 notes payable, shares 3,353,437            
Common stock grants to consultant $ 250 87,250 87,500
Common stock grants to consultant, shares 250,000            
Common stock grants to independent directors $ 777 705,457 706,234
Common stock grants to independent directors, shares 776,753            
Stock based compensation - warrants 5,250,540 5,250,540
Stock based compensation - options $ 5,917,351 5,917,351
Deferred compensation $ (294,264) (294,264)
Net loss $ (16,994,625) (16,994,625)
Balance at Dec. 31, 2014 $ 63,886 $ 46,908,249 $ (294,264) (49,892,282) $ (3,214,411)
Balance, shares at Dec. 31, 2014 63,885,930            
Effect of reverse merger $ (1,402)     1,402    
Effect of reverse merger, shares (1,402,426)            
Stock option exercise $ 25     3,935     $ 3,960
Stock option exercise, shares 25,556           (41,851)
Common stock grants to independent directors $ 458     116,209     $ 116,667
Common stock grants to independent directors, shares 458,170            
Common stock grants to investor relations $ 100     44,900     45,000
Common stock grants to investor relations, shares 100,000            
Stock based compensation - warrants       48,700     48,700
Stock based compensation - options       1,409,592     1,409,592
Deferred compensation         $ 294,264   294,264
Restricted stock issuances $ 6,021     1,800,201     1,806,222
Restricted stock issuances, shares 6,020,725            
Net loss           (4,257,875) (4,257,875)
Balance at Dec. 31, 2015 $ 69,088 $ 50,333,188 $ (54,150,157) $ (3,747,881)
Balance, shares at Dec. 31, 2015 69,087,955            
[1] January 1, 2014 retroactively adjusted to reflect effects of the reverse acquisition transaction.